GSK has secured approval in China for Trelegy Ellipta as a maintenance treatment for adults with asthma, adding to its existing indication in COPD and making it the only single inhaler triple therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback